Navigation Links
Genta Announces Results of Phase 1 Study Using Genasense,Administered by Intermittent Subcutaneous Injection

Study Shows Safety and Pharmacokinetics Similar to IV Doses in Phase 3 CLL Trial

BERKELEY HEIGHTS, N.J., June 06, 2007 /PRNewswire-FirstCall/ -- Genta Incorporated announced the publication of preliminary clinical results that show the Company's lead anti-cancer drug, Genasense(R) (oblimersen sodium) injection, can be safely administered by intermittent subcutaneous (SC) injection, as well as by brief intravenous (IV) infusion. These regimens may eventually reduce or eliminate the current requirements for administering Genasense by continuous IV (CIV) infusion. The new schedules also expand the potential for use in combination with anticancer drugs that are administered on a daily or weekly basis. The data were published in proceedings of the annual meeting of the American Society of Clinical Oncology (ASCO) that was held this week in Chicago, IL.

The SC study used a new formulation of Genasense that was concentrated 5- fold greater than that used in previous Phase 3 trials. In a dose-ranging pharmacokinetic (PK) and pharmacodynamic trial, bolus SC injections of 75, 150 and 225 mg yielded dose-proportional plasma concentrations that were associated with down-regulation of Bcl-2 in blood cells. The 225 mg dose level achieved exposure PK parameters that were similar to levels achieved at the 3 mg/kg CIV daily dose level that was tested in the recent Phase 3 trial of Genasense in chronic lymphocytic leukemia (CLL).

A second phase of the program is testing escalating doses of Genasense administered as a 2-hour IV infusion. Single 150 mg doses, as well as repeated 150 mg doses administered daily for 5 consecutive days, have been well-tolerated. To date, the principal adverse events have been reversible skin reactions at the injection site on the SC schedule and transient fever on the brief IV schedule.

"These highly encouraging data represent important next steps that may greatly improve dosing
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/30/2014)... , Sept. 30, 2014 MiMedx Group, ... medicine company utilizing human amniotic tissue and patent-protected processes ... the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic ... Tom Koob , Ph.D., Chief Scientific Officer, will present ... Koob will present on Tuesday, October 7, 2014, at ...
(Date:9/30/2014)... 30, 2014 Arbor Pharmaceuticals, LLC. - ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - Product ... the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Arbor Pharmaceuticals, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... DENVER , Sept. 30, 2014  According ... "the world of cancer clinical trials is going ... clinical trials and the work of the current ... these types of ,next generation, clinical trials, which ... tomorrow."  The company has been ...
Breaking Medicine Technology:MiMedx to Present at the Stem Cell Meeting on the Mesa 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
... Reportlinker.com announces that a new market research ... Neurostimulation Devices - Global Pipeline ... 2016 http://www.reportlinker.com/p0285077/Neurostimulation-Devices---Global-Pipeline-Analysis--Opportunity-Assessment-and-Market-Forecasts-to-2016.html ... Pipeline Analysis, Opportunity Assessment and Market Forecasts ...
... announces that a new market research report is ... Dysfunction - Pipeline Assessment and Market Forecasts to ... Erectile Dysfunction - Pipeline Assessment and Market ... and healthcare report, "Erectile Dysfunction - Pipeline Assessment ...
Cached Medicine Technology:Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 4Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 5Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 6Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 7Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 8Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 9Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 10Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 11Reportlinker Adds Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017 6
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... the stops to rescue surgical patients in crisis are ... such heroism is questionable, a new study suggests. ... saving elderly patients with life-threatening complications after major surgery, ... senior author Dr. Amir Ghaferi. He is assistant professor ...
(Date:10/1/2014)... The peptide a small protein beta-amyloid is strongly associated ... unequivocal proof that this peptide is the causal agent ... main obstacle impeding such confirmation is that beta-amyloid is ... it aggregates, that is when it self-assembles to form ... with a single target, beta-amyloid alone, but with multiple ...
(Date:10/1/2014)... New research co-funded by the Engineering and Physical ... cyber-security of the UK,s vital industrial control systems ... the electricity grid, and the rail network. ... threats from hackers or malware infiltrating the systems ... Research Institute in Trustworthy Industrial Control Systems (RITICS), ...
(Date:10/1/2014)... 2014 Familylifeinsurancequotes.org has released a ... for senior citizens. , Senior citizens can qualify ... sell coverage to seniors who are over 50 years ... without taking a medical examination. , Term life insurance ... senior clients can qualify. Having life insurance during retirement ...
(Date:10/1/2014)... 01, 2014 Lifeinsurance-policy.com has released ... best life insurance prices for smokers. , Smoking will ... premiums. Comparing quotes is the best method to find ... for customers who need coverage. , Whole life ... of the policy. Since the coverage is permanent, the ...
Breaking Medicine News(10 mins):Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2
... to Integrate with MEDITECH MAGIC Health Information System via ... Information Management , , ... STRM ) today announced that it will ... MEDITECH MAGIC Health Information System of Massena Memorial Hospital, ...
... Dec. 9 Frost & Sullivan, a global ... recently held Manufacturing Summit, hosted the India Manufacturing ... Bangalore. Instituted in 2004, the awards aim to ... manufacturing capabilities and acknowledge the best facilities in ...
... the recent economic downturn, natural health degree ... still experiencing a wellness boom, as holistic ... the Internet,s top natural health career site ... training, chiropractic, nutrition, Reiki and reflexology career ...
... spend weeks in recovery after cosmetic skin treatments can often return ... thanks to an innovative new tool. The Pixel CO2 OMNIFIT device ... three. The technology is among the latest treatment tools available to ... ...
... Roche Molecular Diagnostics,announced today that it has received ... TaqMan(R) HBV Test v2.0, allowing it to be sold,for ... sensitive test offers,Roche,s fully automated real-time PCR technology to ... hepatitis B virus (HBV) DNA in patient,plasma and serum. ...
... Duane Reade Holdings, Inc. today announced the appointment of Mr. ... effective December 1, 2008. Mr. Scorpiniti reports directly to ... adds value and expertise to Duane Reade,s capable management team ... senior executives. , , ...
Cached Medicine News:Health News:Streamline Health(R) Announces Massena Memorial Hospital to Implement Enterprise Document Workflow Solutions 2Health News:Streamline Health(R) Announces Massena Memorial Hospital to Implement Enterprise Document Workflow Solutions 3Health News:Streamline Health(R) Announces Massena Memorial Hospital to Implement Enterprise Document Workflow Solutions 4Health News:Streamline Health(R) Announces Massena Memorial Hospital to Implement Enterprise Document Workflow Solutions 5Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 2Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 3Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 4Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 5Health News:Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier 2Health News:Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier 3Health News:Juva Skin Center's Laser Skin Treatments Take an Innovative Leap with Pixel CO2 Device 2Health News:Improved Testing for Hepatitis B Virus From Roche 2Health News:Improved Testing for Hepatitis B Virus From Roche 3Health News:Duane Reade Holdings, Inc. Further Strengthens Management Team With Addition of Frank Scorpiniti, SVP, Pharmacy Operations 2Health News:Duane Reade Holdings, Inc. Further Strengthens Management Team With Addition of Frank Scorpiniti, SVP, Pharmacy Operations 3
End-gripping forceps with small, concentric rings on each tip. For general purpose membrane grasping, particularly thin membranes, or grasping membranes adherent to the retinal surface....
... design and developmerit of systems for the ... is pleased to present its latest system ... in one compact system. The D.O.R.C. VFI/VFE ... such as silicone oil, with viscosities of ...
... The D.O.R.C. HEXON Illumination System ... Xenon systems offer, with one remarkable ... discharge lamp, a more efficient source ... illumination quality provides a color consistency ...
... The EndoProbe handpieces, used for ... active aspiration, 25 gauge, and illuminating ... provides the ophthalmologist with uncompromised laser ... have 3-meter, fiber-optic cables that are ...
Medicine Products: